Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365402 | 1.00 | AXL (0.53) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL7255706 | 0.88 | AXL (0.77) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29368189 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29468124 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL423202 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL31324910 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29631094 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL105581 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL21393430 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL2656577 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4027999-B1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | MIRATI THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12466838-B2 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | Mirati Therapeutics, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| WO-2024215802-A1 | BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| CN-1280580-A | Thienopyrimidine and thienopyridine derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-01-17 | — | — | CN | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | AXL 3287/4885MKNK1 4085/4885MKNK2 4114/4885 |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | AXL 3291/4885MKNK1 3139/4885MKNK2 3269/4885 |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | AXL 3928/4885MKNK1 3153/4885MKNK2 3105/4885 |
| US-12466838-B2 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | ABL1, LCK, SRC | AXL 57/4885MKNK1 228/4885MKNK2 233/4885 |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | AXL 3578/4885MKNK1 2846/4885MKNK2 3111/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | AXL 2875/4885MKNK1 1138/4885MKNK2 1091/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | AXL 3755/4885MKNK1 391/4885MKNK2 460/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | AXL 1200/4885MKNK1 1096/4885MKNK2 1138/4885 |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | HDAC5, NR5A2, HRH4 | AXL 1875/4885MKNK1 4463/4885MKNK2 4487/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | AXL 2061/4885MKNK1 4073/4885MKNK2 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.